OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Alencar on Unmet Needs Associated With BTK Inhibitor Resistance in CLL

March 17th 2025

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Dr Sheen on Racial Disparities in Physiology, Genetic Testing in Breast Cancer

March 17th 2025

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Dr Herrmann on Assessing Time Toxicity in Lung Cancer Trials

March 17th 2025

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Dr Rampal on ​Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups

March 17th 2025

Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.

Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer

March 17th 2025

Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.

Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

March 16th 2025

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

March 16th 2025

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

Dr Richter on Goals for Expanding T-Cell–Redirecting Therapies in Myeloma

March 14th 2025

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Dr Koehne on ​the Evolution of the Multiple Myeloma Treatment Paradigm

March 14th 2025

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13th 2025

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Dr McGregor on the Rationale of Analyzing the Efficacy and Safety Exposure Response of Tivozanib in RCC

March 13th 2025

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Dr Phillips on Future Avenues for Improving the Management of High-Risk MCL

March 13th 2025

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Dr Nathanson on the Role of Reversion Mutations in PARP Inhibitor Resistance in Breast Cancer

March 13th 2025

Katherine L. Nathanson, MD, discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Dr DeAngelo on the Efficacy of Avapritinib in Advanced Systemic Mastocytosis

March 13th 2025

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Dr Vose on the Safety of Epcoritamab in Relapsed/Refractory LBCL

March 12th 2025

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Dr Komrokji on Unanswered Questions in High-Risk MDS Management

March 12th 2025

Rami Komrokji, MD, discusses how consensus guidelines could address unanswered questions regarding the management of high-risk MDS.

Dr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer Management

March 12th 2025

Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.

Dr Dreyling on the Rationale Behind the TRIANGLE Study in MCL

March 12th 2025

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

Dr McCann on the Ongoing Development of Tailored Treatment Regimens in HER2+ Breast Cancer

March 12th 2025

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

NEXT PAGE
PREVIOUS PAGE